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Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AIC)
represented by autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cell aplasia,
and autoimmune granulocytopenia. The distinction of immune cytopenias from cytopenias due to bone
marrow infiltration, usually associated with a worse outcome and often requiring a different treatment, is
mandatory. AIHA and ITP are more frequently found in patients with unfavorable biological risk factors for
CLL. AIC secondary to CLL respond less favorably to standard treatments than their primary forms, and
treating the underlying CLL with chemotherapy or monoclonal antibodies may ultimately be necessary.
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 Introduction
The clinical course of chronic lymphocytic leukemia (CLL) is frequently complicated by autoimmune cytopenias (AIC), which can affect a sig-
nificant proportion of patients [1]. AIC in CLL include autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pure red cell
aplasia (PRCA) and autoimmune granulocytopenia (AIG) [2–7]. The most frequent forms are AIHA (7–10%) and ITP (1–5%). PRCA is much
rarer (<1%) [6,8] followed by AIG, which has been reported in only 3 out of 1750 patients (0.17%) from a single institution [8].
CLL is generally characterized by profound immunosuppression and, as a consequence, patients are subject to a high rate of infections whose
severity may be increased by concomitant AIC [4,9–12]. AIC may occur at any time during the course of the disease but in a fraction of cases
AIC may precede or be concomitant to CLL diagnosis. It is important to distinguish cytopenias related to non-immune causes (i.e. bone marrow
infiltration) from AIC secondary to the disease, since these latter forms have different prognosis and treatment.
 Pathogenesis of Secondary AIC
Secondary AIC associated to CLL are usually mediated by IgG auto-antibodies that coat red blood cells, granulocytes or platelets, thus promot-
ing their accelerated clearance by the spleen and the liver. Auto-antibodies or self-reacting T-cells can also impair blood cells production by inter-
fering with erythroblasts or megakaryocytes maturation in the bone marrow as in PRCA and ITP. Moreover, in vitro studies have shown that
natural killer (NK) cells are able to directly lyse erythroblasts. About 90% of AIC in CLL are due to polyclonal high-affinity immunoglobulin G
(IgG) antibodies produced by non-malignant B-cell clones directed against red blood cell (RBC) or platelet membrane antigens [13]. Malignant
CLL clone may also produce autoimmune antibodies, usually of the immunoglobulin M class (IgM), in less than 10% of AIC [14–16]. In addition
to autoreactive antibodies, several other immune mediated mechanisms have been described that may interfere with blood cells production, such
as direct inhibition of erythro- or megakaryo-cytopoiesis by cytotoxic T-cells and NK-cells, also secreting inhibitory cytokines. Dysregulation of
the microenvironment induced by soluble factors secreted by malignant cells and consequent T-cell dysfunction are variably involved [2,4].
Historically, CLL has been viewed as a tumor caused by the accumulation of long-lived resting lymphocytes carrying intrinsic apoptotic defects.
However, in recent years, this model has been challenged, after many experiments have shown that CLL contains a sizeable fraction of actively
proliferating cells [4,17]. These cells are released in the peripheral blood after recirculating through the microenvironment of the proliferative cen-
ters of the lymph-nodes where they are “recharged” and endowed with increased migratory potential before becoming quiescent again [18,19]. It
is emerging that the capability of a CLL cell to participate in the proliferation centers is strongly influenced by the characteristics of its B receptor
(BCR) and by its interaction with (auto)antigens, aspects that are strongly influenced by the mutational status of the immunoglobulin heavy-chain
variable (IGHV) gene [9,17,19,20]. The IGHV mutational status defines two disease subgroups: the first characterized by no or very few somatic
mutation of the IGHV gene (U-CLL); the second displaying several somatic mutations (M-CLL) [21,22]. While M-CLL and U-CLL share a largely
similar gene expression profile (GEP), differences in clinical behavior exist and are relevant [23]. In fact, U-CLL predicts for a worse outcome and
a higher prevalence of AIC [24–29]. Unlike M-CLL, whose BCR is quiescent and unable to transmit external signals to the cell nucleus, U-CLL B-
cells are responsive to external stimuli by binding (auto)antigens, thus promoting their survival and proliferation [20]. U-CLL B-cells have an
increased ability to phosphorylate p72 (SYK) and ZAP-70 molecules in response to surface IgM ligation by an antigen, providing evidence for an
intact downstream signaling pathway of their BCR [30]. This translates in a more aggressive clinical behavior of U-CLL, which might be induced
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by the frequent (auto)antigenic interactions with their BCR, thus acti-
vating otherwise quiescent CLL B-cells. Similarly, the preferential
occurrence of ITP and AIHA, as well as of isolated positive direct
anti-globulin test (DAT) in U-CLL, may also reflect propensity of
this clone to interact with other cells of the immune system and with
the microenvironment [24,31].
The role of antigen stimulation on BCR configuration and activity
is further highlighted by the evidence that more than 20% of CLL
patients exhibit closely homologous “stereotyped” heavy chain
complementary-determining region 3 (HCDR3) sequences and
approximately 1% of these also carry virtually identical IGHV amino-
acid sequences [32–36]. These findings suggest that clones sharing
stereotyped BCRs may have expanded through stimulations by a
restricted set of epitopes, which may play an important role in CLL
pathogenesis [17]. Importantly, an association has been reported
between specific stereotyped BCR configurations and occurrence of
ITP and AIHA, further stressing the potential role of (auto)antigen
stimulation in the pathogenesis of AIC [25,29]. In particular it has
been shown that the risk of developing ITP was higher among patients
with stereotyped subset #1 (IGHV1–5-7/IGHD6–19/IGHJ4) and #7
(IGHV1–69 or IGHV3–30/IGHD3-3/IGHJ6); instead, a higher risk of
developing AIHA was associated with subset #3 (IGHV1–69 and
IGHV4–30/IGHD2-2/IGHJ6).
Beside the role of BCR on CLL clone, a series of additional cellular
events are likely to be implicated in the induction of AIC. It is
hypothesized that CLL cells themselves may act as antigen-presenting
cells (APC), inducing the formation of auto-reactive T helper cells.
This would occur through the production of B-cell activator factor
and a proliferation-inducing ligand, which is facilitated by the pres-
ence of nonfunctional T regulatory cells (T-regs), which impairs
immune surveillance [37,38]. The impaired function of T-regs, that in
normal conditions have a key role in preventing autoimmune phe-
nomena, is typical of patients with CLL and is even worsened by the
use of cytotoxic drugs [39–42]. Although several authors reported
that T-regs are increased in CLL patients few data are available
describing T-regs functions in patients with CLL in the course of
autoimmune phenomena [43,44]. The interaction between neoplastic
B-cells and T-regs through CD27-CD70 linking apparently lowers T-
regs susceptibility to apoptosis and confers functional impairment
[45]. The functional impairment of T-regs may prevent the elimina-
tion of non-neoplastic autoreactive T- and B-cells, as witnessed by
reports indicating that T-regs have the potential to treat immune-
mediated disease [46,47].
More recently, Toll-like receptors (TLR), which represent major
agents of innate immunity and play an important role in the activation
of normal B-lymphocytes, were found to be abnormally expressed in
CLL, with a reduction of TLR2 and TLR4 and an increase of TLR7,
TLR9, and TLR10 [48,49]. Patients with reduced TLR4 had an
increased risk of development of autoimmune complications, suggest-
ing that impaired expression of these molecules may be associated with
reduced ability to silence autoreactive phenomena [50].
Historically, the association between fludarabine used as a single
agent and AIHA onset has been a major concern, so that treatment
guidelines [51–54] considered treatment with fludarabine contraindi-
cated in patients with previous episodes of AIC. This paradigm has
changed after fludarabine has been routinely used in association with
other drugs (i.e. cyclophosphamide) and monoclonal antibodies (i.e.
rituximab), which strongly lowered the risk of secondary AIC [55].
However, cytotoxic treatments may still complicate the homeostasis
of the immune system, as frequently reported for cladribine, pentosta-
tin or alemtuzumab [56–58]. Recently it was reported that alemtuzu-
mab treatment may facilitate ITP development outside CLL [59].
Figure 1 summarizes the main pathogenetic mechanisms involved
in AIC development.
 Diagnostic Criteria for Secondary AIC
AIHA
All common causes of anemia should be taken into account in the
differential diagnosis (i.e. iron or vitamins deficiencies, occult
Figure 1. Secondary AIC associated to CLL are usually mediated by IgG auto-antibodies produced by non-malignant B-cell clones (1), that promote acceler-
ated clearance of blood cells in the spleen and liver. Malignant CLL clone may also produce autoimmune antibodies, usually of the immunoglobulin M class
(IgM), in less than 10% of AIC (2). CLL cells can act as antigen-presenting cells, favoring the emergence of autoreactive T helper cells and non-functional T
regulatory cells (T-regs), through CD27-CD70 interaction (3). T-regs are usually increased in number but result functionally impaired. CLL cells may behave as
immunoregulatory B-cells, by producing immunosuppressive cytokines, including TGF-beta and IL10, when stimulated by external signals (4). Autoreactive T/
NK cytotoxic cells, on their own, may interfere with megakaryocyte maturation and erythroid precursors (as in PRCA), by releasing inhibitory cytokines or
with a direct cytotoxic effect (5).
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bleeding, chronic inflammatory conditions, sepsis etc) particularly in
patients with an indolent course of the disease. In patients with more
advanced or active disease, bone marrow failure, hypersplenism and
recent chemotherapy should be excluded.
Once alternative causes of anemia have been ruled out, the diagno-
sis of AIHA is confirmed in the presence of all the following criteria
[27,60].
1. Hb levels lower than or equal to 110 g/L, in the absence of any
cytotoxic treatment in the preceding month;
2. One or more laboratory signs of hemolysis (increased unconju-
gated bilirubin, elevated lactic dehydrogenase, reduced
haptoglobin);
3. Either reticulocytosis or positive direct antiglobulin test (DAT).
Laboratory signs of hemolysis may be misleadingly altered in CLL.
This makes the diagnosis of AIHA sometimes difficult, especially in
cases with negative DAT. Alteration of LDH levels may be related to
disease progression, haptoglobin may be influenced by underlying
inflammation, while increased bilirubin levels may result from recent
administration of cytotoxic therapy. Reticulocytosis may be absent
when bone marrow function is conditioned by infiltration of leukemic
cells, or inhibited by chemotherapy.
While DAT represents the most important and useful diagnostic
tool, its negativity does not necessarily exclude an antibody mediated
pathogenesis of the anemia. In fact DAT negative AIHA have been
documented in CLL [61], as in 1 to 10% of patients with primary
AIHA [58]. Despite the nearly equivalent clinical characteristics
between DAT positive and negative AIHA [62], it was suggested an
hypothetic difference in cytokine pattern [63] and/or IgG subclass
[64]. DAT negative AIHA may be due to the presence of autoanti-
bodies of IgA class or of low-affinity, or to reduced amount of RBC-
bound IgG molecules below the threshold of the test (around 400
molecules per erythrocyte). In these cases, the use of mono-specific
antisera against IgA, low ionic strength solutions or cold washings, or
more sensitive tests (microcolumn and solid-phase) can be indicated.
More sophisticated techniques (enzyme-linked and radiolabeled tests,
flow-cytometry and mitogen-stimulated DAT), that are not routine in
the majority of laboratories, can detect up to 30 to 40 molecules of
anti-RBC autoantibodies. In particular, the latter have been proposed
as functional methods able to detect anti-RBC antibodies in about 1/3
of secondary AIHA associated to CLL [65].
The distinction between “warm” and “cold” AIHA is of great
importance in terms of diagnosis, treatment and prognosis. Cold
forms are rarer and are generally classified as cold hemoagglutinin dis-
ease (CHD). CHD is due to IgM, which are able to fix complement (I/
i system) more efficiently than other isotypes, display an optimal tem-
perature of reaction at 4C, and prevalently cause intravascular hemo-
lysis. Warm AIHA are instead generally due to IgG directed against
epitopes of the Rh system, which react at 37C, and determine
extravascular hemolysis. The hemolytic process occurring in vivo in
the intravascular compart, mainly due to IgM autoantibodies, is esti-
mated to destroy ten times more red cells compared to the IgG-
mediated extravascular hemolysis that takes place in the spleen [61].
Rare cases of AIHA caused by IgM “warm” autoantibodies exist.
They present with severe hemolysis and are clinically more insidious
compared to patients with other types of AIHA. A correct diagnosis
is often difficult because it requires serologic work-up that should
include the dual DAT to detect both IgM and IgG antibodies [66].
Finally, it is worth reminding that DAT positivity in the course of
CLL may be due not only to autoantibodies, but also to alloantibod-
ies, especially in patients with history of red cells transfusions and in
multiparous females. Such antibodies are sometimes responsible for
severe hemolytic reactions following transfusion [61].
In such a complex scenario, bone marrow evaluation is strongly
suggested when diagnosis remains questionable in order to exclude
neoplastic infiltration or development of myelodisplastic syndrome/
secondary acute leukemia, especially in older patients with a long his-
tory of CLL. In addition, peripheral blood smear examination repre-
sents always an easy and fast diagnostic tool that adds important
information on cell morphology, including the presence of schisto-
cytes, that should be absent in AIHA.
ITP
The lack of a sufficiently sensitive and specific auto-antibody test,
able to parallel the performance of DAT for red blood cells, repre-
sents a major limitation in the interpretation of thrombocytopenia
developing in the course of CLL. The following criteria have been
proposed [27,67,68] in order to make a diagnosis of secondary ITP
associated to CLL, recently renamed secondary ITP (CLL-associated)
according to the new standard terminology [69].
1. Fall (at least half of the initial level and below 100 3 109/L) of
the platelet count that is otherwise unexplained (e.g. not drug-
induced);
2. Normal or augmented number of megakaryocytes in the bone
marrow aspirate or biopsy;
3. No or limited (not palpable) splenomegaly;
4. No cytotoxic treatment in the last month;
5. Exclusion of other causes of thrombocytopenia.
Common causes of thrombocytopenia in CLL are splenomegaly,
bone marrow failure secondary to tumor infiltration, recent chemo-
immunotherapy, failure to recover a normal count due to megakaryo-
cyte dysplasia [70]. Peripheral blood smear examination should be part
of the diagnostic tool in order to rule out pseudo-thrombocytopenia.
Exclusion of disseminate intravascular coagulation, thrombotic throm-
bocytopenic purpura and/or heparin-induced thrombocytopenia is also
required. Acute infections (bacterial, viral, fungal) or coexisting chronic
infection such as helicobacter pylorii, human immunodeficiency virus
(HIV), hepatitis C, and drug induced thrombocytopenia should be
ruled out by clinical and laboratory analysis [69,71].
Bone marrow evaluation remains crucial for diagnosing secondary
ITP. However, in patients with Binet C stage and extensive bone mar-
row involvement, the interpretation of the number of megakaryocytes
is sometimes problematic. In these cases, essential requisites for the
diagnosis of ITP will be the lack of response to platelet transfusion
(in patients without known refractoriness to platelet concentrates)
and/or a rapid (<1 week) response to high-dose intravenous Ig
(IVIg). Lack of response to platelet transfusion will be defined as the
failure to obtain satisfactory responses in terms of bleeding or platelet
number to two or more platelet transfusions [71]. For patients whose
ITP was diagnosed at the time of CLL presentation the same diagnos-
tic criteria should be applied, although the time of the fall of the pla-
telet count cannot be established in patients presenting with no data
on their previous platelet count.
As mentioned before, platelet antibody assays aimed at measuring
the autoantibodies bound to platelets have limited diagnostic utility
mainly because of very low specificity, but can be useful in selected
complicated cases. Finally it should be noted that about 30% of ITP
cases also have simultaneous AIHA (Evans Syndrome) [72].
PRCA
The diagnosis of secondary PRCA associated to CLL should be
considered in any patient with anemia and reticulocytopenia [5,73].
When PRCA is suspected, signs of hemolysis and peripheral blood
smear examination should be investigated in order to rule out
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hemolysis. PRCA is characterized by profound reticulocytopenia with
normal bilirubin and LDH levels, and it should thus be distinguish-
able from AIHA. It should be noted that the reticulocyte count
expressed as a percentage of red cells (and not as absolute number)
can be misleadingly normal in the presence of severe anemia.
Definite diagnosis relies on bone marrow biopsy which will show
selective red cell aplasia with virtual total absence of erythroid precur-
sors. Characteristic defects of erythroblast maturation may also be
present on residual erythroid precursors. Anti-glycophorin immuno-
histochemistry may facilitate identification of red cell precursors
when the bone marrow is overcrowded by lymphocytes.
PRCA can be seen in association with other AIC making the diagno-
sis sometimes difficult. Viral infections such as Epstein–barr virus and
Parvovirus B19 should be excluded [74], as well as HIV and viral B
and C hepatitis. Blood levels of folic acid and vitamin B12 will need to
be ascertained. Finally, the concomitant presence of a thymoma should
be excluded by means of patient history and radiographic examina-
tions. Acquired forms of secondary PRCA associated to CLL will be
easily distinguished from congenital forms, such as Diamond-Blackfan
anemia, Fanconi anemia, and congenital dyserythropoietic anemias by
patient age and history. Finally, a distinction between myelodysplastic
syndrome with erythroid hypoplasia and PRCA should be considered
in the differential diagnosis, especially in elderly patients with CLL.
Again, in the PRCA setting more than in any other AIC, bone marrow
aspirate and biopsy are important for a correct diagnosis.
AIG
Secondary autoimmune granulocytopenia (AIG) occurs rarely in
CLL, and should be suspected in patients with isolated neutropenia
and no other apparent cause [5]. AIG diagnostic criteria still remain
elusive and AIG can be considered a diagnosis of exclusion.
Initial diagnostic work up should include patient history. A history
of recurrent infections years before CLL diagnosis may point to the
presence of a congenital or acquired disturbance of immunity, which
should be ruled out with ad-hoc investigations. Detailed review of
peripheral smear is mandatory in order to look for infection marks (i.e.
Dohle bodies), dysplastic elements and nutritional deficiencies. It is
important to exclude any other cause of secondary immune neutrope-
nia such as systemic lupus erythematosus, rheumatoid arthtritis, Sjog-
ren syndrome, celiac disease, hyperthyroidism (Graves disease), Chron
disease and other (auto)immune diseases [75]. Concomitant large
granular lymphocyte leukemia (T-LGL), which is a common cause of
secondary AIG, should be excluded by means of flow cytometry and
blood smear morphology [76]. Rituximab therapy has been associated
with a late onset (>4 weeks after exposure) neutropenia [77]. The
pathogenesis of this alteration is still unknown. Voog et al. [78] have
described IgG antibodies able to bind neutrophils while others consider
AIG a consequence of disturbances in B cell recovery [79]. Recent
reports suggested a higher incidence of this complication among HIV,
in patients treated with purine analogs such as fludarabine, and those
with marked B-lymphocyte depletion and low serum IgM [80].
Although not conclusive, the presence of normo/hyper cellular bone
marrow with late maturation arrest of the granulocytes may favor the
diagnosis of secondary AIG. The anti-neutrophil antibody test repre-
sents a potentially useful diagnostic tool both in primary and secondary
AIG. The direct anti neutrophil antibody test is characterized by lim-
ited discriminating power and it is not still well standardized being
affected by high false positive rate [81,82]. Conversely, indirect anti
neutrophil antibody test seems more precise and reproducible [75].
Lack of coverage of the full human neutrophil antigens pattern in neu-
trophil suspension is the major determinant of the limited sensitivity
of this test. In the largest study conducted in primary AIG, sensitivity
of the indirect test was 74% at first assessment and further increased
on repeated determination [83]. In case the first test is negative or bor-
der line, it is recommended to repeat the test up to four or more times
over a time-span of 4 to 6 months or longer [84].
Impact of AIC on patients outcome
CLL is characterized by a marked clinical heterogeneity, ranging
from patients with several years of stable disease and a normal life
expectancy to patients with rapidly progressive disease [1,9]. Next-
generation sequencing techniques have recently added new independ-
ent and reliable markers that can predict tumor aggressiveness [85–
87]. However, although less stylish, the “old fashioned” classifications
described by Rai and Binet about 30 years ago are still the most
widely used easy-to-make prognostic scores [88,89]. In both classifica-
tions, cytopenias are associated with poor prognosis in CLL, yielding
an advanced stage of the disease. The cause of the cytopenias was not
considered in the original Rai and Binet classifications, while the
recently modified staging systems of the National Cancer Institute
Working Group (NCIWG) do require that the cytopenias are related
to bone marrow failure caused by CLL [1]. Thus, while not all cyto-
penias are associated with poor prognosis once reverted to normal
values according to current classification (i.e. iron or vitamin B12/
folate deficiency), the prognostic implications of AIC still represent a
matter of debate and remain controversial [27,60,67,68,90].
Some of the major reasons for this uncertainty rely in the time of
AIC presentation, which may variably extend before or after CLL diag-
nosis, the high variability of cytotoxic treatments and their interplay
with tumor/AIC response; the lack of consistency in the way overall
survival is measured, whether from the time of CLL diagnosis (which
may be several years before the onset of AIC), or from the time of AIC
onset. Furthermore, clinical presentation and association of secondary
ITP and AIHA with biological characteristic of the underlying CLL can
vary greatly, as summarized in Table I. The known association between
AIC and adverse biological prognostic factors such as U-CLL or
adverse cytogenetic has often hampered the significance of univariate
survival analysis. Finally, time to onset of AIHA and ITP from CLL
diagnosis is also different, as shown in Fig. 2, with ITP occurring ear-
lier, when CLL is usually not active or quiescent, while AIHA is more
frequently associated to advanced or progressive disease.
Despite all these uncertainties, in a recent study from Moreno et al.,
patients with AIC at diagnosis (stage C “immune”) have been associ-
ated with better outcome than those in whom cytopenia was due to
bone marrow failure (stage C “infiltrative”), though their survival was
inferior to patients with uncomplicated stage A [67]. In another series
of CLL patients seen in the Division of Hematology at Mayo Clinic,
survival from onset of cytopenia was reported to be significantly better
for patients with AIC (median 9.1 years) compared to patients with
BM failure (median 4.4 years, P< 0.001) [60]. Although authors con-
cluded that cytopenia caused by AIC was not an adverse prognostic
factor, the reported survival for patients developing early AIC was in
TABLE I. Clinical and Biological Characteristics of CLL Patients Developing
AIHA or ITP
AIHA ITP
Active disease Usually yes Usually not
Rai and Binet stage Advanced Any
Median time from CLL diagnosis (mo) 39 20
Refractory to standard treatment (%) 16 32
Prognostic significance on OS Unclear Possible
Unfavorable cytogenetic deletion (%) 40 40
Un-mutated IGHV (%) 60–70 80
Stereotyped HCDR3 (%) 29 50
AIHA: autoimmune hemolytic anemia; ITP: immune thrombocytopenia;
IGHV: immunoglobulin heavy-chain variable region; HCDR: heavy-chain
complementarity determining region-3.
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the range of Binet stage B patients rather than stage A. In line with
this, a recent study focused on AIC diagnosed at CLL presentation,
reporting that patients with stage C “immune” had significantly worse
overall survival than stage A patients (P< 0.0001), but not different
from stage B (P5 0.14) [68]. Importantly, the latter series relied on
patients treated with modern approaches that included the systematic
use of monoclonal antibodies together with cytotoxic treatment.
An Italian study investigated clinical, therapeutic, and prognostic
features of AIHA in the course of CLL reporting that AIHA had no
independent effect on survival [91]. On the other hand, Dearden et al
assessed the prognostic effect of a positive DAT in patients with CLL
treated for the first time. A positive DAT predicted a poorer response
to treatment and together with AIHA was associated with a lower
overall survival, particularly among patients treated with fludarabine
as single agent [92]. It is important to note, however, that the latter
study was performed in a subset of patients with CLL that required
treatment, which is a different group of patients than those who are
diagnosed with a clinically apparent AIHA or than consecutive CLL
patients presenting to a hospital. In terms of ITP, Visco et al. reported
that this complication was associated with an inferior outcome, which
could be partly explained by the association between ITP and U-CLL
[27]. The prognostic impact of ITP was dependent on the time of
onset of thrombocytopenia. The same group reported that later onset
of AIHA in the course of CLL had a negative effect on outcome com-
pared to early onset [28]. These results were replicated in a recent mul-
ticenter report, where occurrence of AIHA was significantly associated
with U-CLL and/or unfavorable cytogenetic lesions [25].
The apparently inferior survival of CLL patients developing AIC
may be explained by higher risk of infections, bleeding and cardiovas-
cular complication associated with AIC onset and treatment, but a
similarly plausible reason is that AIC represent a clinical expression
of CLL clone aggressiveness. The latter theory is supported by the
evidence that both AIHA and ITP were consistently associated with
U-CLL, higher CD38 and ZAP-70 expression and unfavorable cytoge-
netic lesions (i.e. del11q23 and del17p13) in several independent
series [25,67,68,90,91,93].
 Treatment
No prospective randomized trials are available to guide the man-
agement of AIC secondary to CLL. The majority of information
comes from retrospective studies or case reports. It is widely accepted
that cases occurring with progression of the underlying disease will
require CLL-specific cytotoxic treatment, and/or an anti-CD20 mono-
clonal antibody [94]. On the other hand, patients with isolated AIC,
in absence of CLL progression, should be managed as indicated for
patients with primary forms of autoimmune cytopenias.
AIHA, first line treatment
The decision to start a specific treatment of AIHA relies on hemo-
globin level and associated symptoms, and transfusion is required
only for symptomatic cases with severe anemia.
For AIHA caused by warm antibodies, the first line therapy is pred-
nisone at a dose of 1 mg/kg per day given for 3 to 4 weeks, which is
then slowly tapered off during the following 1 to 2 months. The alter-
native regimen of repeated courses of pulsed high dose dexamethasone
(40 mg/day for 4 consecutive days), which is considered equivalent to
standard prednisone in primary AIC, warrants further investigations
in terms of efficacy and safety in the CLL setting. If a rapid response
is needed (i.e. patients with massive hemolysis), immunoglobulin infu-
sion (IVIg) may be administered (1 g/kg on days 1 and 2).
In case of AIHA caused by cold antibodies (CHD), corticosteroid
treatment is much less effective. In fact, while corticosteroids are usu-
ally effective in about two-thirds of warm AIHA, they are able to
control hemolysis in roughly only 15% of CHD. Accordingly, the use
of corticosteroids is usually discouraged as first line therapy in CHD.
Moreover, while warm and mixed cases usually display a severe onset
with symptomatic anemia requiring prompt treatment, CHD may
have a milder presentation. Thus the decision to treat CHD should
be reserved to patients with transfusion dependent symptomatic ane-
mia, and/or with disabling circulatory symptoms. In these cases ritux-
imab is recommended as first-line treatment.
ITP, first line treatment
Specific treatment is indicated in patients with platelet count below
30 3 109/L or in case of bleeding signs or symptoms. Bleeding rarely
occurs above 50 3 109/L [69,71]. Platelet transfusion could be
required in case of life-threatening hemorrhages.
The first line therapy is prednisone at a dose of 1 mg/kg per day
given for 3 to 4 weeks, which is then tapered off. A more prolonged
course at full dosage with slow tapering (in terms of several weeks) is
suggested by some authorities. As already stated for AIHA, pulsed
high dose dexamethasone warrants further investigations in terms of
efficacy and safety in the CLL setting. If a rapid response is needed
(i.e. in ITP patients with significant bleeding or prior to splenec-
tomy), IVIg may be administered (1 g/kg on days 1 and 2).
ITP response rates to specific therapies are lower in comparison to
the figures generally reported for the idiopathic counterpart. Approxi-
mately one fifth of patients are refractory to standard approaches
[27], which is greater than what has been reported for primary ITP
(9%). Response to steroids occurs in roughly half of patients, which is
in the lower part of the range of responses to steroids reported for
primary ITP (50 to 75%). On the other hand, while approximately
80% of primary ITP patients usually respond to IVIg, only half of
patients with secondary ITP respond to IVIg alone [6,27], making
CLL related ITP a pretty insidious complication of the disease.
AIHA, second line treatment
Patients, who do not respond to conventional upfront therapy
within 4 to 6 weeks should be considered for alternative treatment
strategies. Refractory or relapsed patients should always be investi-
gated again to exclude other causes of anemia such as marrow failure
or CMV reactivation or parvovirus B19 infection [7].
Cyclophosphamide may be considered in patients who fail to
respond to corticosteroids, require higher maintenance doses, or fail
to sustain a prolonged response. Other immunosuppressive agents
used in primary AIHA, such as low dose cyclosporine, mycophenolate
mofetil, or azathioprine are possible alternative therapies.
Figure 2. Time to AIHA and ITP development from CLL diagnosis (time 0),
obtained from representative cohorts of patients with CLL [25,27,28].
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Monoclonal antibodies able to target clonal and non-clonal CLL B-
cells offer a valid therapeutic option in refractory cases [95]. Although
this therapy as single agent is well tolerated and may induce signifi-
cant responses, only a small fractions of patients achieve durable
remissions [95–98]. Rituximab is generally administered at the dose
scheduled for the treatment of lymphomas (375 mg/m2/weekly for 4
weeks), while lower doses (100 mg fixed dose for 4 weekly infusions)
have been tested only in the setting of primary AIHA [99]. In a
cohort of steroid-refractory patients with AIHA secondary to CLL
treated with rituximab as single agent [98], a complete (CR) and par-
tial response (PR) were achieved in 22% and 50% of cases, respec-
tively. At a mean follow-up of 17 months, about 40% of patients
were transfusion-free.
Different groups tested the combination of rituximab with cyto-
toxic drugs. These approaches emphasize the role of “CLL-directed
treatment” in AIC, targeting the non-neoplastic B/T-cell population
and neoplastic CLL B-cells, thus inhibiting inflammatory cascades
and the cross-talk between all these cells. Kaufman et al. treated with
rituximab, cyclophosphamide, and dexamethasone (RCD) a cohort of
CLL patients with refractory AIC [100]. All patients with AIHA
responded to treatment with a median duration of response of 22
months. Patients converting DAT from positive to negative had lon-
ger response duration compared to patients never achieving negativity
(41 months vs. 10 months). The same regimen was used in a cohort
of 48 CLL patients including 26 AIHA, 9 ITP, and 8 Evan’s syn-
drome. Overall, RCD achieved 89.5% response rate, irrespective of
the AIC subtype, but relapse occurred in almost 40% of patients with
a median response duration of 24 months [101,102]. Another effec-
tive regimen is rituximab, cyclophosphamide, vincristine and predni-
sone (R-CVP) that showed a significant activity in cohorts of CLL
patients with refractory ITP/AIHA with a median time to next treat-
ment for AIC of 21.7 months [103].
More recently, alemtuzumab has been reported as a possible alter-
native therapy, especially for patients with severe, refractory second-
ary AIHA, who have not previously responded to conventional
therapy [104]. A number of new monoclonal antibodies, such as
ofatumumab and obinotuzumab are currently investigated in CLL
and their activity in CLL-related autoimmune cytopenias should be
evaluated in future studies [94].
ITP, second line treatment
Alternative treatments for refractory or relapsed patients include
monoclonal antibodies6 chemotherapy. These regimens induce a suf-
ficiently rapid response in the majority of patients.
In refractory secondary ITP, rituximab monotherapy given at the
usual dose of 375 mg/m2/weekly for 4 weeks was associated with an
encouraging overall response of 86%, with 57% of patients achieving
CR [105]. These rates compare favorably with refractory secondary
AIHA associated to CLL (see previous paragraph), making rituximab
an appealing option in this setting. The mean duration of response
was 21 months. The combination of rituximab with cytotoxic regi-
mens (RCD and R-CVP), as for AIHA, were also associated with a
high rate of responses (nearly 90%) that lasted for an average of 20
to 24 months [101–103].
Although splenectomy efficacy is well established in primary ITP, this
procedure may worsen immunodeficiency and risk of infections in CLL
patients. Furthermore, many CLL patients cannot be candidate to sur-
gery due to their old age and/or important comorbidities. For this rea-
son, although effective (50–70% of patients experiencing a long-term
response) [27], splenectomy should be reserved to highly selected cases.
Few case reports suggest that TPO-mimetics may represent an effi-
cacious therapeutic approach in refractory secondary ITP [106–109].
These novel ITP specific treatments might spare these patients not
only from bleeding risk but also from toxic or inappropriate cytotoxic
therapies, not otherwise demanded by the burden of the underlying
disease. Two studies for the treatment of secondary ITP associated to
CLL with eltrombopag are ongoing in Italy and United States, and
preliminary results are awaited soon (ClinicalTrials.gov Identifier:
NCT01610180; NCT01168921).
PRCA
The primary goal in PRCA is to induce the recovery of erythro-
poiesis avoiding an excess of transfusions. Several treatment
regimens usually effective in autoimmune conditions fail in secondary
PRCA, especially when this condition is associated to CLL or
lymphoma.
PRCA is generally poorly responsive to corticosteroids, and cyclo-
sporine represents the treatment of choice. Patients usually require
prolonged treatment or combination therapy to maintain remission,
thus increasing the risk of infections [7,70]. Most patients will require
long-term low-dose maintenance therapy [110,111]. Response should
be monitored by measuring the absolute reticulocyte count, which
usually increases within 2 to 3 weeks from initiation of therapy while
substantial improvements in the hemoglobin level can take up to
months.
There are case reports of successful treatment of patients with
PRCA with rituximab [73,112] or alemtuzumab [113,114] as single
agents, but the response rate is lower than for AIHA or ITP. The
mechanism of action of rituximab in PRCA is not entirely clear.
The rapid response that has been observed in some patients raises the
possibility of mechanisms different from those thought to be active in
other AIC [112]. Interestingly, IVIg have been reported to be effective
in some cases of PRCA associated to parvovirus B19 infection
because they contain neutralizing antibodies against the virus [74].
Rossignol et al. [102], recently reported the efficacy of RCD combi-
nation in five PRCA patients. All five patients obtained CR and only
one patient relapsed.
AIG
The course of AIG is usually benign. Most cases resolve spontane-
ously within one to three weeks, while other require specific treat-
ment [81]. When the absolute neutrophil count is below 500/mL, the
risk of infection is significantly increased. The standard approach to
AIG is represented by the administration of granulocyte colony-
stimulating factor (G-CSF), which usually improves or resolves neu-
tropenia within few days. However, neutropenia often recurs after
discontinuation of the treatment. For this reason patients should be
monitored over time to prevent relapses or serious infective complica-
tions. Prophylactic antibiotics are indicated in persistent neutropenia,
especially as secondary prophylaxis.
Splenectomy was commonly used before the availability of G-CSF
but results were discouraging. Sirolimus, cyclosporine and IVIg have
also been reported to be sometimes beneficial in AIG [76–78]. Mono-
clonal antibodies such as rituximab and alemtuzumab can provide
long lasting remissions but reports are limited.
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